Literature DB >> 32619490

Management of Secondary Genomic Findings.

Alexander E Katz1, Robert L Nussbaum2, Benjamin D Solomon3, Heidi L Rehm4, Marc S Williams5, Leslie G Biesecker6.   

Abstract

Secondary genomic findings are increasingly being returned to individuals as opportunistic screening results. A secondary finding offers the chance to identify and mitigate disease that may otherwise be unrecognized in an individual. As a form of screening, secondary findings must be considered differently from sequencing results in a diagnostic setting. For these reasons, clinicians should employ an evaluation and long-term management strategy that accounts for both the increased disease risk associated with a secondary finding and the lower positive predictive value of a screening result compared to an indication-based testing result. Here we describe an approach to the clinical evaluation and management of an individual who presents with a secondary finding. This approach enumerates five domains of evaluation-(1) medical history, (2) physical exam, (3) family history, (4) diagnostic phenotypic testing, and (5) variant correlation-through which a clinician can distinguish a molecular finding from a clinicomolecular diagnosis of genomic disease. With this framework, both geneticists and non-geneticist clinicians can optimize their ability to detect and mitigate genomic disease while avoiding the pitfalls of overdiagnosis. Our goal with this approach is to help clinicians translate secondary findings into meaningful recognition, treatment, and prevention of disease. Published by Elsevier Inc.

Mesh:

Year:  2020        PMID: 32619490      PMCID: PMC7332641          DOI: 10.1016/j.ajhg.2020.05.002

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  48 in total

1.  Genetic screening: programs, principles, and research--thirty years later. Reviewing the recommendations of the Committee for the Study of Inborn Errors of Metabolism (SIEM).

Authors:  A P Simopoulos
Journal:  Public Health Genomics       Date:  2008-09-14       Impact factor: 2.000

2.  Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?

Authors:  Joaquin Chapa; Alyson Haslam; Vinay Prasad
Journal:  Mayo Clin Proc       Date:  2019-06       Impact factor: 7.616

3.  Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium.

Authors:  Laura M Amendola; Gail P Jarvik; Michael C Leo; Heather M McLaughlin; Yassmine Akkari; Michelle D Amaral; Jonathan S Berg; Sawona Biswas; Kevin M Bowling; Laura K Conlin; Greg M Cooper; Michael O Dorschner; Matthew C Dulik; Arezou A Ghazani; Rajarshi Ghosh; Robert C Green; Ragan Hart; Carrie Horton; Jennifer J Johnston; Matthew S Lebo; Aleksandar Milosavljevic; Jeffrey Ou; Christine M Pak; Ronak Y Patel; Sumit Punj; Carolyn Sue Richards; Joseph Salama; Natasha T Strande; Yaping Yang; Sharon E Plon; Leslie G Biesecker; Heidi L Rehm
Journal:  Am J Hum Genet       Date:  2016-05-12       Impact factor: 11.025

4.  Genetic identification of familial hypercholesterolemia within a single U.S. health care system.

Authors:  Noura S Abul-Husn; Kandamurugu Manickam; Laney K Jones; Eric A Wright; Dustin N Hartzel; Claudia Gonzaga-Jauregui; Colm O'Dushlaine; Joseph B Leader; H Lester Kirchner; D'Andra M Lindbuchler; Marci L Barr; Monica A Giovanni; Marylyn D Ritchie; John D Overton; Jeffrey G Reid; Raghu P R Metpally; Amr H Wardeh; Ingrid B Borecki; George D Yancopoulos; Aris Baras; Alan R Shuldiner; Omri Gottesman; David H Ledbetter; David J Carey; Frederick E Dewey; Michael F Murray
Journal:  Science       Date:  2016-12-23       Impact factor: 47.728

5.  Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines.

Authors:  Cynthia L Neben; Anjali D Zimmer; Will Stedden; Jeroen van den Akker; Robert O'Connor; Raymond C Chan; Elaine Chen; Zheng Tan; Annette Leon; Jack Ji; Scott Topper; Alicia Y Zhou
Journal:  J Mol Diagn       Date:  2019-06-11       Impact factor: 5.568

6.  Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes.

Authors:  Jennifer J Johnston; Wendy S Rubinstein; Flavia M Facio; David Ng; Larry N Singh; Jamie K Teer; James C Mullikin; Leslie G Biesecker
Journal:  Am J Hum Genet       Date:  2012-06-14       Impact factor: 11.025

7.  Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.

Authors:  Zanfina Ademi; Gerald F Watts; Jing Pang; Eric J G Sijbrands; Frank M van Bockxmeer; Peter O'Leary; Elizabeth Geelhoed; Danny Liew
Journal:  J Clin Lipidol       Date:  2014-06-12       Impact factor: 4.766

8.  Cost-effectiveness analysis of stocking dantrolene in ambulatory surgery centers for the treatment of malignant hyperthermia.

Authors:  Taiwo Aderibigbe; Barbara H Lang; Henry Rosenberg; Qixuan Chen; Guohua Li
Journal:  Anesthesiology       Date:  2014-06       Impact factor: 7.892

9.  Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing.

Authors:  Joshua W Knowles; Daniel J Rader; Muin J Khoury
Journal:  JAMA       Date:  2017-07-25       Impact factor: 56.272

10.  Are physicians prepared for whole genome sequencing? a qualitative analysis.

Authors:  K D Christensen; J L Vassy; L Jamal; L S Lehmann; M J Slashinski; D L Perry; J O Robinson; J Blumenthal-Barby; L Z Feuerman; M F Murray; R C Green; A L McGuire
Journal:  Clin Genet       Date:  2015-07-07       Impact factor: 4.438

View more
  4 in total

1.  Genetic Testing for Heritable Cardiovascular Diseases in Pediatric Patients: A Scientific Statement From the American Heart Association.

Authors:  Andrew P Landstrom; Jeffrey J Kim; Bruce D Gelb; Benjamin M Helm; Prince J Kannankeril; Christopher Semsarian; Amy C Sturm; Martin Tristani-Firouzi; Stephanie M Ware
Journal:  Circ Genom Precis Med       Date:  2021-08-20

2.  A systematic literature review of disclosure practices and reported outcomes for medically actionable genomic secondary findings.

Authors:  Julie C Sapp; Flavia M Facio; Diane Cooper; Katie L Lewis; Emily Modlin; Philip van der Wees; Leslie G Biesecker
Journal:  Genet Med       Date:  2021-08-26       Impact factor: 8.864

3.  Interpretation of Incidental Genetic Findings Localizing to Genes Associated With Cardiac Channelopathies and Cardiomyopathies.

Authors:  Jordan E Ezekian; Catherine Rehder; Priya S Kishnani; Andrew P Landstrom
Journal:  Circ Genom Precis Med       Date:  2021-08-13

4.  Genetic counseling for patients with positive genomic screening results: Considerations for when the genetic test comes first.

Authors:  Marci L B Schwartz; Adam H Buchanan; Miranda L G Hallquist; Christopher M Haggerty; Amy C Sturm
Journal:  J Genet Couns       Date:  2021-03-31       Impact factor: 2.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.